D. Present

A. Kornbluth, D. Present, T. Ullman, 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Post Hoc Analysis

P. Rutgeerts, S. Hanauer, B. Sands, 2022, The SAGE Encyclopedia of Research Design.

The state of the art in the management of inflammatory bowel disease.

S. Hanauer, D. Present, 2003, Reviews in gastroenterological disorders.

Medical management of the pregnant patient with inflammatory bowel disease.

D. Present, A. Steinlauf, 2004, Gastroenterology clinics of North America.

The Effect on the Fetus of Medications Used to Treat Pregnant Inflammatory Bowel-Disease Patients

C. Bodian, D. Present, E. Scherl, 2004, American Journal of Gastroenterology.

Long‐term Infliximab Maintenance Therapy for Ulcerative Colitis: The ACT‐1 and ‐2 Extension Studies

P. Rutgeerts, S. Hanauer, B. Sands, 2012, Inflammatory bowel diseases.

Rifaximin for the treatment of active pouchitis: A randomized, double‐blind, placebo‐controlled pilot study

R. Sandler, S. Hanauer, D. Wolf, 2007, Inflammatory bowel diseases.

Repifermin (keratinocyte growth factor‐2) for the treatment of active ulcerative colitis: a randomized, double‐blind, placebo‐controlled, dose‐escalation trial

B. Sands, D. Wolf, W. Sandborn, 2003, Alimentary pharmacology & therapeutics.

An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial.

S. Targan, M. Kamm, C. Hawkey, 2001, Gastroenterology.

How to do without steroids in inflammatory bowel disease.

D. Present, 2000, Inflammatory bowel diseases.

Adverse Events Associated With the Use of Cyclosporine in Patients With Inflammatory Bowel Disease

A. Kornbluth, D. Present, S. Lichtiger, 2008, The American Journal of Gastroenterology.

Relapses of Inflammatory Bowel Disease During Pregnancy: In-Hospital Management and Birth Outcomes

A. Kornbluth, D. Present, S. Kane, 2008, The American Journal of Gastroenterology.

Transvaginal approach for repair of rectovaginal fistulae complicating Crohn's disease.

D. Present, J. Bauer, H. Jaffin, 1991, Annals of surgery.

The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn’s disease who failed prior infliximab therapy

J. Chao, D. Binion, D. Present, 2010, Alimentary pharmacology & therapeutics.

Medical Management of Inflammatory Bowel Disease

D. Present, B. Mehl, Rosa Sottile, 1989, DICP : the annals of pharmacotherapy.

Withdrawal of corticosteroids in inflammatory bowel disease patients after dependency periods ranging from 2 to 45 years: a proposed method

J. Mechanick, D. Present, L. Anderson, 2009, Alimentary pharmacology & therapeutics.

W1105 Cyclosporine and Infliximab As Delayed Salvage Therapy for Each Other in Patients with Steroid-Refractory Ulcerative Colitis

A. Kornbluth, D. Present, T. Ullman, 2009 .

Infliximab therapy for ulcerative colitis: many unanswered questions

D. Present, 2001, American Journal of Gastroenterology.

Frequency of inflammatory bowel disease in offspring of couples both presenting with inflammatory bowel disease.

D. Present, P. Rubin, R. A. Bennett, 1991, Gastroenterology.

Infliximab therapy for Crohn's disease fistulae: Number of infusions required for response and time to relapse

C. Bodian, D. Present, E. Scherl, 2000 .

T1127 Adalimumab Safety in Patients with Crohn's Disease and Previous Exposure to Infliximab: CHOICE Trial

D. Binion, D. Present, J. Kent, 2008 .

Obstructive hydronephrosis. A frequent but seldom recognized complication of granulomatous disease of the bowel.

P. Banks, D. Present, J. Rabinowitz, 1969, The New England journal of medicine.

Screening and surveillance colonoscopy in chronic Crohn's colitis: results of a surveillance program spanning 25 years.

N. Harpaz, C. Bodian, D. Present, 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

The long-term outcome of ulcerative colitis treated with 6-mercaptopurine.

C. Bodian, D. Present, P. Rubin, 1996, The American journal of gastroenterology.

Ciprofloxacin as a treatment for ulcerative colitis-not yet.

D. Present, Daniel H. Present, 1998, Gastroenterology.

Favorable effect of 6-Mercaptopurine on fistulae of Crohn's disease

D. Present, B. Korelitz, 2005, Digestive Diseases and Sciences.

What is the Role of Immunosuppressive Therapy in Inflammatory Bowel Disease

D. Present, 1982 .

How to do without steroids in inflammatory bowel disease.

D. Present, 2000, Inflammatory bowel diseases.

Is mycophenolate mofetil a new alternative in the treatment of inflammatory bowel disease?

D. Present, 1999, Gut.

Inflammatory bowel disease related osteonecrosis: report of a large series with a review of the literature

A. Kornbluth, D. Present, A. Shah, 2005, Alimentary pharmacology & therapeutics.

Prognosis of lymphoma in patients following treatment with 6‐mercaptopurine/azathioprine for inflammatory bowel disease

I. Shapira, D. Present, B. Korelitz, 2012, Inflammatory bowel diseases.

Desensitization to sulfasalazine after hypersensitivity reactions in patients with inflammatory bowel disease.

D. Present, B. Korelitz, P. Rubin, 1984, Journal of clinical gastroenterology.

Crohn’s fistula: current concepts in management1

D. Present, 2003 .

Crohn's fistula: current concepts in management.

D. Present, 2003, Gastroenterology.

6-Mercaptopurine Is Effective in Crohn’s Disease Without Concomitant Steroids

D. Present, J. Marion, E. Goldstein, 2004, Inflammatory bowel diseases.

Shortcomings of the National Crohn's Disease Study: the exclusion of azathioprine without adequate trial.

D. Present, B. Korelitz, 1981, Gastroenterology.

Complete bowel obstruction following initial response to infliximab therapy for crohn's disease: A series of a newly described complication

A. Kornbluth, D. Present, E. Scherl, 2000 .

Intravenous Cyclosporine in Refractory Pyoderma Gangrenosum Complicating Inflammatory Bowel Disease

D. Present, E. Scherl, P. Rubin, 2001, Inflammatory bowel diseases.

Methotrexate for Crohn's disease.

D. Present, B. Korelitz, 1995, The New England journal of medicine.

Is Perianal Crohn's Disease Associated with Intestinal Fistulization?

T. Bayless, C. Bodian, V. Annese, 2005, The American Journal of Gastroenterology.

Practice Patterns in the Use of Anti-Tumor Necrosis Factor Alpha Agents in the Management of Crohn’s Disease: A US National Practice Survey Comparing Experts and Non-Experts

D. Present, B. Lebwohl, A. Swaminath, 2011, Digestive Diseases and Sciences.

Efficacy of cyclosporine in treatment of fistula of crohn's disease

D. Present, S. Lichtiger, 1994, Digestive Diseases and Sciences.

Management of Fistula Disease

D. Present, 1998 .

Cyclosporin for severe ulcerative colitis: a user's guide.

S. Hanauer, A. Kornbluth, D. Present, 1997, The American journal of gastroenterology.

Nature and course of pancreatitis caused by 6-mercaptopurine in the treatment of inflammatory bowel disease.

S. Meltzer, D. Present, B. Korelitz, 1986, Gastroenterology.

Post-operative prophylaxis with 6-MP, 5-ASA or placebo in Crohn's disease: A 2 year multicenter trial*

P. Rutgeerts, M. Peppercorn, D. Present, 1998 .

A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease

S. Targan, P. Rutgeerts, S. Hanauer, 1997 .

Metastatic Crohn's disease.

M. Lebwohl, P. G. Prioleau, D. Present, 1984, Journal of the American Academy of Dermatology.

Extraintestinal manifestations in patients with diverticulitis.

D. Present, D. Sachar, M. Cerulli, 1988, Annals of internal medicine.

Cyclosporin in Inflammatory Bowel Disease

D. Present, S. Lichtiger, 1990 .

A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease.

P. Rutgeerts, S. Hanauer, R. Modigliani, 2002, Gastroenterology.

6-Mercaptopurine and other immunosuppressive agents in the treatment of Crohn's disease and ulcerative colitis.

D. Present, 1989, Gastroenterology clinics of North America.

Olsalazine sodium in the treatment of ulcerative colitis among patients intolerant of sulfasalazine. A prospective, randomized, placebo-controlled, double-blind, dose-ranging clinical trial.

D. Present, D. Sachar, H. Janowitz, 1987, Gastroenterology.

6-Mercaptopurine in Crohn's fistulas

D. Present, B. Korelitz, 1985 .

Infliximab for induction and maintenance therapy for ulcerative colitis.

Paul Rutgeerts, Allan Olson, Suzanne Travers, 2005, The New England journal of medicine.

Anti-interleukin-12 antibody for active Crohn's disease.

M. Neurath, P. Mannon, C. Elson, 2004, The New England journal of medicine.

The Effect of Intravenous Cyclosporine on Rates of Colonic Surgery in Hospitalized Patients With Severe Crohn’s Colitis

A. Kornbluth, D. Present, M. Lazarev, 2012, Journal of clinical gastroenterology.

Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.

S. Targan, P. Rutgeerts, M. Spehlmann, 2007, Gastroenterology.

Evaluation of 22 genetic variants with Crohn's Disease risk in the Ashkenazi Jewish population: a case-control study

R. Desnick, L. Mayer, D. Present, 2011, BMC Medical Genetics.

Cyclosporine is Safe and Effective in Patients With Severe Ulcerative Colitis

D. Present, J. Stern, A. Cheifetz, 2011, Journal of clinical gastroenterology.

Screening and surveillance colonoscopy in chronic Crohn's colitis.

N. Harpaz, C. Bodian, D. Present, 2001, Gastroenterology.

Neutropenia is not required for clinical remission during azathioprine therapy in inflammatory bowel disease

D. Present, Kimberly M. Persley, 2001, European journal of gastroenterology & hepatology.

Fistula response to methotrexate in Crohn's disease: a case series

D. Present, U. Mahadevan, J. Marion, 2003, Alimentary pharmacology & therapeutics.

The prevention of Crohn's disease after surgery: metronidazole is a small but continuous medical advancement.

D. Present, 1995, Gastroenterology.

Long term response of Crohn's disease to treatment with 6-mercaptopurine

D. Present, B. Korelitz, N. Wisch, 1978 .

Impaired Lymphocyte Responsiveness in Inflammatory Bowel Disease

D. Present, B. Korelitz, D. Sachar, 1973 .

Review article: the efficacy of infliximab in Crohn’s disease — healing of fistulae

D. Present, 1999, Alimentary pharmacology & therapeutics.

Immunotherapy in inflammatory bowel disease.

D. Present, D. Sachar, 1978, The Medical clinics of North America.

Urinary tract fistulas in Crohn's disease: surgery versus medical therapy.

D. Present, 2002 .

The use of 6-mercaptopurine in adolescents with Crohn's disease.

D. Present, B. Korelitz, 1991, Gastroenterology.

Immunosuppressive Drugs: Do They Have Any Role in the Treatment of IBD?

D. Present, 1990 .

Chromoendoscopy-Targeted Biopsies Are Superior to Standard Colonoscopic Surveillance for Detecting Dysplasia in Inflammatory Bowel Disease Patients: A Prospective Endoscopic Trial

N. Harpaz, J. Waye, C. Bodian, 2008, The American Journal of Gastroenterology.

Consensus conference: Colorectal cancer screening and surveillance in inflammatory bowel disease.

D. Present, S. Itzkowitz, Steven H Itzkowitz, 2005, Inflammatory bowel diseases.

Colonoscopic polypectomy in chronic colitis: conservative management after endoscopic resection of dysplastic polyps.

N. Harpaz, J. Waye, D. Present, 1999, Gastroenterology.

The roentgenographic features of ureteral obstruction secondary to granulomatous disease of the bowel.

P. Banks, D. Present, J. Rabinowitz, 1971, Clinical radiology.

Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis.

P. Rutgeerts, S. Hanauer, B. Sands, 2011, Gastroenterology.

Granulomatous colitis in association with diverticula.

D. Present, H. Janowitz, R. Marshak, 1970, The New England journal of medicine.

The IBD1 locus for susceptibility to Crohn’s disease has a greater impact in Ashkenazi Jews with early onset disease

M. Daly, J. Silver, B. Gelb, 2001 .

The IBD1 locus for susceptibility to Crohn's disease has a greater impact in Ashkenazi Jews with early onset disease

M. Daly, J. Silver, B. Gelb, 2001, American Journal of Gastroenterology.

Section editor's commentary. The role of panca and asca in differentiating ulcerative colitis, Crohn's disease, and indeterminate colitis

P. Banks, D. Present, 2007 .

The Role of pANCA and ASCA in Differentiating Ulcerative Colitis, Crohnʼs Disease, and Indeterminate Colitis

P. Banks, D. Present, 1999 .

Crohn's disease of the duodenum associated with pancreatitis: a case report and review of the literature.

D. Present, A. Aufses, L. Newman, 1987, The Mount Sinai journal of medicine, New York.

Interaction of 6-mercaptopurine and azathioprine with 5-aminosalicylic acid agents.

D. Present, 2000, Gastroenterology.

T1139 The ACT Trials: Incremental Benefit of Second and Third Induction Doses of Infliximab in Patients with Moderately-to-Severely Active Ulcerative Colitis (UC)

P. Rutgeerts, S. Hanauer, B. Sands, 2008 .

Is medical prophylaxis indicated for the prevention of recurrence of Crohn's disease after surgery?

P. Banks, D. Present, 1995, Inflammatory bowel diseases.

Mucosal Healing in Patients with Ulcerative Colitis Associates with a Reduced Colectomy Risk, High Incidence of Symptomatic Remission, and Corticosteroid-Free State: 1200

P. Rutgeerts, S. Hanauer, B. Sands, 2010 .

Maintenance oral sulfasalazine prolongs remission in ulcerative proctitis and proctosigmoiditis.

C. Bodian, D. Present, P. Rubin, 1991, The American journal of gastroenterology.

Urinary tract fistulas in Crohn's disease: surgery versus medical therapy

D. Present, 2002, American Journal of Gastroenterology.

488 Early Institution of Tinidazole May Prevent Pouchitis Following Ileal-Pouch Anal Anastomosis (IPAA) Surgery in Ulcerative Colitis (UC) Patients

Steven J Brown, D. Present, M. Lazarev, 2010 .

Is cyclosporine as effective in chronic ul cerative colitis as in severe ulcerative colitis

A. Kornbluth, D. Present, H. Janowitz, 1998 .

Pouch-ouch

D. Present, E. Maser, 2008, Current opinion in gastroenterology.

Granulomatous colitis--pathogenetic concepts.

D. Present, H. Janowitz, 1966, Gastroenterology.

T1142 Infliximab Treatment for Ulcerative Colitis: Clinical Response, Clinical Remission, & Mucosal Healing in Patients with Moderate or Severe Disease in the Active Ulcerative Colitis Trials (ACT1 & ACT2)

P. Rutgeerts, W. Sandborn, O. Dabbous, 2008 .

What is the best initial treatment and maintenance therapy for distal ulcerative colitis?

P. Banks, D. Present, 1996, Inflammatory bowel diseases.

Medical decompression of toxic megacolon by "rolling". A new technique of decompression with favorable long-term follow-up.

D. Present, P. Rubin, M. Chapman, 1988, Journal of clinical gastroenterology.

Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial.

J. Ellenberg, S. Hanauer, B. Sands, 2008, Gastroenterology.

The Current Role of Immunosuppressives in the Treatment of Inflammatory Bowel Disease

D. Present, B. Korelitz, 1986 .

Malabsorption and metastatic melanoma.

D. Present, B. Benisch, S. Abramson, 1972, The Mount Sinai journal of medicine, New York.

Chromoendoscopy Is More Effective Than Standard Colonoscopy in Detecting Dysplasia During Long-term Surveillance of Patients With Colitis.

N. Harpaz, J. Waye, C. Bodian, 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Spontaneous umbilical fistula in granulomatous (Crohn's) disease of the bowel.

D. Present, P. Hiley, N. Cohen, 1971, Gastroenterology.

Rosiglitazone for Active Ulcerative Colitis

J. Ellenberg, S. Hanauer, B. Sands, 2009 .

6-Mercaptopurine/Azathioprine remains an important contributor in managing Crohn's disease.

D. Present, B. Korelitz, 2014, Journal of Crohn's & Colitis.

Granulomatous diseases of the gastrointestinal tract.

D. Present, H. Janowitz, A. Lindner, 1966, Annual Review of Medicine.

Olsalazine in the treatment of ulcerative colitis among patients intolerant of sulphasalazine: a prospective, randomized, placebo-controlled, double-blind, dose-ranging clinical trial.

D. Present, D. Sachar, H. Janowitz, 1988, Scandinavian journal of gastroenterology. Supplement.

Olsalazine sodium in the treatment of ulcerative colitis among patients intolerant of sulfasalazine

D. Present, D. Sachar, H. Janowitz, 1987 .